A Study Called NATION-OS to Learn About the Link Between N-terminal proBNP (NT-proBNP) Levels and Medical Problems Due to Heart Failure (HF) in German Patients With HF

NT-proBNP Assessment in a HFrEF Population in Germany

NCT04915118•Bayer

Summary

Researchers are looking for a better way to treat heart failure (HF), a condition in which the heart does not pump blood as well as it should. Research has shown that the levels of a hormone called N-terminal proBNP (NT-proBNP) in the body can be used for differential diagnosing of HF. NT-proBNP is released by the heart when there is an increase in heart pressure. The levels of NT-proBNP can indicate whether medical problems are likely to happen due to HF. These medical problems are called "decompensation events." The higher a person's NT-proBNP levels is expected, the higher their risk of developing HF and having decompensation events. So, the researchers in this study want to learn about NT-proBNP levels and decompensation events in German patients with a common type of HF called heart failure with reduced ejection fraction (HFrEF). In patients with HFrEF, the muscle on the left chamber of the heart does not pump blood as well as it should. The researchers will collect information from patients and their health records for about 300 adult patients in Germany with HFrEF who have been receiving standard of care treatment for their condition. Standard of care treatments are treatments that doctors commonly use to treat patients. The researchers will study and record the levels of NT-proBNP levels and any changes in the health of the patients at time of NT-proBNP measurement. The researchers will collect this information between May 2021 and September 2021. The patients in this study : * have had any HF-decompensation event since January 2016 * have had at least 1 NT-proBNP measurement done before the study The researchers will collect the following information about the patients: * the results of NT-proBNP measurements * the date of the NT-proBNP measurements * the number and type of decompensation events

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Female or male patient, aged 18 years or older at the time of HF diagnosis
•Diagnosis of heart failure with reduced ejection fraction confirmed by echocardiography
•Patient on HFrEF standard of care treatment with guideline-based therapy
•One or more HF decompensation(s) within observation period defined as HFH or the need for IV diuretic treatment
•Signed informed consent if patient is alive at start of data collection
•At least one NT-proBNP value available prior enrollment, fulfilling the below criteria:
•* NT-proBNP value was assessed in an outpatient setting exactly at 01-JAN-2016 or later
•* NT-proBNP value was assessed and within six months after a decompensation event within observational period.
•* At time of NT-proBNP measurement patients need to be hemodynamically stable without signs of residual congestion

Exclusion Criteria

•At time of NT-proBNP measurement
•Participation in an investigational program with interventions outside of routine clinical practice
•Awaiting heart transplantation or has/anticipates receiving an implanted ventricular assist device
•Has acute coronary syndrome (unstable angina, non-ST elevation myocardial infarction, or ST elevation myocardial infarction) or coronary revascularization (coronary artery bypass grafting or percutaneous coronary intervention) Estimated glomerular filtration rate (eGFR) calculated based on the Modification of Diet in Renal Disease (MDRD) equation \< 15 ml/min/1.73m2 or chronic dialysis
•Severe hepatic insufficiency (CHILD Pugh C)
•Acute inflammatory disease
•Malignancy
•Treatment with Vericiguat (which may be available to patients in Germany in Q3 2021 but not at time of protocol development)

Locations (1)

Many locations

Multiple Locations, Germany

Key Dates

Start Date

June 17, 2021

Primary Completion Date

November 30, 2021

Completion Date

November 30, 2021

Last Updated

December 2, 2022

Enrollment

169

ACTUAL participants

Conditions

Heart Failure (HF)

Interventions

Decompensation event

OTHER

Left Bundle Branch Pacing in Patients With Hypertrophic Cardiomyopathy After Myectomy

NCT07372196

HCM - Hypertrophic CardiomyopathySudden Cardiac Death+3 more

View study

COMPLETED

SchlaHF-XT-Register. Sleep Disordered Breathing in Heart Failure Register

NCT02301689

Heart Failure (HF)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 2, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study Called NATION-OS to Learn About the Link Between N-terminal proBNP (NT-proBNP) Levels and Medical Problems Due to Heart Failure (HF) in German Patients With HF

Inclusion Criteria

Exclusion Criteria

Left Bundle Branch Pacing in Patients With Hypertrophic Cardiomyopathy After Myectomy

SchlaHF-XT-Register. Sleep Disordered Breathing in Heart Failure Register

Phase 4 Study to Demonstrate Prognostic Usefulness of AdreView™ Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience Death During 60 Months Follow-up.

Open-label, Test-retest Study Assessing Reproducibility of Quantitative Measurements of Myocardial Uptake of AdreView.